ArticleChest2026
Demographic and Physiological Differences Between Fibrotic and Nonfibrotic CT Subtypes of Sarcoidosis.
Article in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundOne approach to categorizing patients using chest CT imaging manifestations of pulmonary sarcoidosis is to use 3 classifications: fibrotic, nonfibrotic, or no parenchymal abnormality. This study aimed to evaluate the relationships between these imaging subtypes and demographic and physiological variables in a large group of patients with sarcoidosis with chest CT imaging. RESEARCH QUESTION: Do individuals with fibrotic sarcoidosis have more severe physiological impairment than those with nonfibrotic sarcoidosis and those with no parenchymal abnormality, and are there CT subtypes of fibrosis that are associated with different physiological subtypes? STUDY DESIGN AND
methodsThe study included individuals with sarcoidosis from 2 large medical centers who were seen between 2008 and 2018 and from the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) consortium and who received high-resolution CT imaging and spirometry and lung diffusing capacity within 180 days (N = 932). Pulmonary function phenotypes were characterized based on spirometry findings and lung diffusing capacity. CT patterns were systematically classified as fibrotic, nonfibrotic, or no parenchymal abnormality based on standardized visual assessment. Multinomial logistic regression analyzed the relationship between pulmonary function and CT categories.
resultsAmong the 942 patients, 353 (38%) had fibrosis, 380 (41%) had nonfibrotic abnormalities, and 199 (21%) had no parenchymal abnormality. Individuals with fibrotic abnormalities were older and had a longer time since diagnosis, more impaired spirometry and diffusing capacity, and larger pulmonary artery diameter than those without (all, P < .001). Among participants with fibrosis, those with a conglomerate mass were 9 times more likely to have a mixed pattern of spirometric impairment (P < .01).
interpretationOur results show that individuals with fibrotic pulmonary sarcoidosis display distinct demographic and spirometric differences. Subtypes of fibrosis exhibit different lung function abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.